477 related articles for article (PubMed ID: 19743457)
1. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
Kaufmann P; Thompson JL; Levy G; Buchsbaum R; Shefner J; Krivickas LS; Katz J; Rollins Y; Barohn RJ; Jackson CE; Tiryaki E; Lomen-Hoerth C; Armon C; Tandan R; Rudnicki SA; Rezania K; Sufit R; Pestronk A; Novella SP; Heiman-Patterson T; Kasarskis EJ; Pioro EP; Montes J; Arbing R; Vecchio D; Barsdorf A; Mitsumoto H; Levin B;
Ann Neurol; 2009 Aug; 66(2):235-44. PubMed ID: 19743457
[TBL] [Abstract][Full Text] [Related]
2. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.
Levy G; Kaufmann P; Buchsbaum R; Montes J; Barsdorf A; Arbing R; Battista V; Zhou X; Mitsumoto H; Levin B; Thompson JL
Neurology; 2006 Mar; 66(5):660-3. PubMed ID: 16534103
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
[TBL] [Abstract][Full Text] [Related]
4. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
Ferrante KL; Shefner J; Zhang H; Betensky R; O'Brien M; Yu H; Fantasia M; Taft J; Beal MF; Traynor B; Newhall K; Donofrio P; Caress J; Ashburn C; Freiberg B; O'Neill C; Paladenech C; Walker T; Pestronk A; Abrams B; Florence J; Renna R; Schierbecker J; Malkus B; Cudkowicz M
Neurology; 2005 Dec; 65(11):1834-6. PubMed ID: 16344537
[TBL] [Abstract][Full Text] [Related]
5. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial.
Sanoobar M; Dehghan P; Khalili M; Azimi A; Seifar F
Nutr Neurosci; 2016; 19(3):138-43. PubMed ID: 25603363
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
[TBL] [Abstract][Full Text] [Related]
7. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
9. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"--a multinational trial.
Mortensen SA
Biofactors; 2003; 18(1-4):79-89. PubMed ID: 14695923
[TBL] [Abstract][Full Text] [Related]
10. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.
Dalla Bella E; Bersano E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Filosto M; Giannini F; Spataro R; Lunetta C; Mandrioli J; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Tugnoli V; Verriello L; Volanti P; Furlan R; Nolan JM; Abgueguen E; Tramacere I; Lauria G
Brain; 2021 Oct; 144(9):2635-2647. PubMed ID: 33905493
[TBL] [Abstract][Full Text] [Related]
11. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
12. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
Mortensen SA; Rosenfeldt F; Kumar A; Dolliner P; Filipiak KJ; Pella D; Alehagen U; Steurer G; Littarru GP;
JACC Heart Fail; 2014 Dec; 2(6):641-9. PubMed ID: 25282031
[TBL] [Abstract][Full Text] [Related]
13. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
[TBL] [Abstract][Full Text] [Related]
14. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
Fang T; Al Khleifat A; Meurgey JH; Jones A; Leigh PN; Bensimon G; Al-Chalabi A
Lancet Neurol; 2018 May; 17(5):416-422. PubMed ID: 29525492
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer.
Lesser GJ; Case D; Stark N; Williford S; Giguere J; Garino LA; Naughton MJ; Vitolins MZ; Lively MO; Shaw EG;
J Support Oncol; 2013 Mar; 11(1):31-42. PubMed ID: 22682875
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
[TBL] [Abstract][Full Text] [Related]
17. Coenzyme Q10 as a possible treatment for neurodegenerative diseases.
Beal MF
Free Radic Res; 2002 Apr; 36(4):455-60. PubMed ID: 12069110
[TBL] [Abstract][Full Text] [Related]
18. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
Andrews JA; Cudkowicz ME; Hardiman O; Meng L; Bian A; Lee J; Wolff AA; Malik FI; Shefner JM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):259-266. PubMed ID: 29402141
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
[TBL] [Abstract][Full Text] [Related]
20. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
Mortensen AL; Rosenfeldt F; Filipiak KJ
Cardiol J; 2019; 26(2):147-156. PubMed ID: 30835327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
